Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79


Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes.

Joshi H, Nord SH, Frigessi A, Børresen-Dale AL, Kristensen VN.

BMC Genomics. 2012 May 22;13:199. doi: 10.1186/1471-2164-13-199.


A negative feedback regulatory loop associates the tyrosine kinase receptor ERBB2 and the transcription factor GATA4 in breast cancer cells.

Hua G, Zhu B, Rosa F, Deblon N, Adélaïde J, Kahn-Perlès B, Birnbaum D, Imbert J.

Mol Cancer Res. 2009 Mar;7(3):402-14. doi: 10.1158/1541-7786.MCR-08-0175. Epub 2009 Mar 10.


Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells.

Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R.

J Biol Chem. 2005 Jul 1;280(26):24428-34. Epub 2005 May 3.


Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.

Gatza ML, Kung HN, Blackwell KL, Dewhirst MW, Marks JR, Chi JT.

Breast Cancer Res. 2011 Jun 7;13(3):R62. doi: 10.1186/bcr2899.


Molecular mechanism of transcriptional repression of gelsolin in human breast cancer cells.

Dong Y, Asch HL, Ying A, Asch BB.

Exp Cell Res. 2002 Jun 10;276(2):328-36.


Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue.

Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):17-23. Review.


Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.

Cuadros M, Cano C, López FJ, López-Castro R, Concha A.

Pathobiology. 2013;80(1):32-40. doi: 10.1159/000339431. Epub 2012 Jul 24.


Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.

Baumbusch LO, Myhre S, Langerød A, Bergamaschi A, Geisler SB, Lønning PE, Deppert W, Dornreiter I, Børresen-Dale AL.

Mol Cancer. 2006 Oct 20;5:47.


Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.

Smith DD, Saetrom P, Snøve O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.

BMC Bioinformatics. 2008 Jan 28;9:63. doi: 10.1186/1471-2105-9-63.


Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized.

Li Y, Pan J, Li JL, Lee JH, Tunkey C, Saraf K, Garbe JC, Whitley MZ, Jelinsky SA, Stampfer MR, Haney SA.

Mol Cancer. 2007 Jan 18;6:7.


The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters.

Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):219-24. Review.


Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53.

Marreiros A, Czolij R, Yardley G, Crossley M, Jackson P.

Gene. 2003 Jan 2;302(1-2):155-64.


Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells.

Delacroix L, Begon D, Chatel G, Jackers P, Winkler R.

DNA Cell Biol. 2005 Sep;24(9):582-94.


The human transcription factor activation protein-2 gamma (AP-2gamma): gene structure, promoter, and expression in mammary carcinoma cell lines.

Li M, Wang Y, Yu Y, Nishizawa M, Nakajima T, Ito S, Kannan P.

Gene. 2002 Nov 13;301(1-2):43-51.


E2F-1 represses transcription of the human telomerase reverse transcriptase gene.

Crowe DL, Nguyen DC, Tsang KJ, Kyo S.

Nucleic Acids Res. 2001 Jul 1;29(13):2789-94.


P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.

Paredes J, Albergaria A, Oliveira JT, Jerónimo C, Milanezi F, Schmitt FC.

Clin Cancer Res. 2005 Aug 15;11(16):5869-77.


Expression of the human oestrogen receptor-alpha gene is regulated by promoter F in MG-63 osteoblastic cells.

Lambertini E, Penolazzi L, Giordano S, Del Senno L, Piva R.

Biochem J. 2003 Jun 15;372(Pt 3):831-9.

Supplemental Content

Support Center